STAT+: Vertex may face another battle in the U.K. over the value of its cystic fibrosis medicines
STAT
NOVEMBER 6, 2023
In draft guidance published late last week, the National Institute for Health and Care Excellence stated that a groundbreaking treatment called Trikafta and two other cystic fibrosis medications sold by the company offer notable clinical benefits, but are not cost-effective.
Let's personalize your content